Edition:
India

Adamis Pharmaceuticals Corp (ADMP.OQ)

ADMP.OQ on NASDAQ Stock Exchange Capital Market

1.60USD
9:21pm IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.60
Open
$1.60
Day's High
$1.62
Day's Low
$1.59
Volume
14,152
Avg. Vol
64,458
52-wk High
$5.10
52-wk Low
$1.50

Latest Key Developments (Source: Significant Developments)

Adamis Pharmaceuticals Announces Patent Litigation Regarding Its Higher Dose Naloxone Injection Product
Tuesday, 21 May 2019 

May 21 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES PATENT LITIGATION REGARDING ITS HIGHER DOSE NALOXONE INJECTION PRODUCT.ADAMIS PHARMACEUTICALS CORP - RECEIVED NOTICE THAT IT HAD BEEN NAMED AND SERVED AS A DEFENDANT IN A LAWSUIT FILED BY KALÉO INC.ADAMIS PHARMACEUTICALS - COMPLAINT ALLEGES CO'S PRODUCT CANDIDATE INFRINGES PATENTS PURPORTEDLY HELD BY KALÉO RELATING TO NALOXONE AUTO-INJECTOR PRODUCT.ADAMIS PHARMACEUTICALS CORP - ADAMIS DOES NOT ANTICIPATE STAY WOULD INTERRUPT OR DELAY FDA'S ONGOING REVIEW OF NDA.ADAMIS - IF PATENT DISPUTE IS UNRESOLVED BY THE TIME FDA PREPARED TO GRANT APPROVAL, AGENCY WOULD GRANT CONDITIONAL APPROVAL UNTIL SOONER OF OCT 4, 2021.ADAMIS PHARMACEUTICALS - BELIEVES NALOXONE INJECTION PRODUCT DOES NOT INFRINGE ANY VALID AND ENFORCEABLE PATENT HELD BY KALÉO.  Full Article

Adamis Pharmaceuticals Submits New Drug Application To FDA For Its Naloxone Pre-Filled Syringe
Tuesday, 1 Jan 2019 

Dec 31 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS NEW DRUG APPLICATION TO FDA FOR ITS NALOXONE PRE-FILLED SYRINGE.  Full Article

Adamis Pharmaceuticals Announces FDA Acceptance For Review For The Supplemental New Drug Application
Monday, 12 Feb 2018 

Feb 12 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE FOR REVIEW FOR THE SUPPLEMENTAL NEW DRUG APPLICATION OF ITS LOW DOSE SYMJEPI PRODUCT CANDIDATE.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA FURTHER INDICATED THAT NO POTENTIAL REVIEW ISSUES WERE IDENTIFIED.ADAMIS PHARMACEUTICALS CORP - FDA INDICATED IF NO MAJOR DEFICIENCIES IDENTIFIED, THEY ARE TARGETING SEPTEMBER 3, 2018 TO COMMUNICATE PROPOSED LABELING.  Full Article

Adamis Pharmaceuticals Announces Submission Of Investigational New Drug (Ind) Application To The FDA
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE FDA FOR NEW PRODUCT CANDIDATE FOR THE TREATMENT OF OPIOID OVERDOSE.  Full Article

Adamis Pharma Submits Prior Approval Supplement To FDA For The Pediatric Version Of Symjepi
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - Adamis Pharmaceuticals Corp ::ADAMIS PHARMACEUTICALS SUBMITS PRIOR APPROVAL SUPPLEMENT TO FDA FOR THE PEDIATRIC VERSION OF SYMJEPI.ADAMIS PHARMACEUTICALS CORP - SUBMISSION OF A PRIOR APPROVAL SUPPLEMENT TO U.S. FOOD AND DRUG ADMINISTRATION FOR PEDIATRIC VERSION (0.15MG) OF SYMJEPI.  Full Article

Adamis Pharmaceuticals gets FDA approval for co's epinephrine pre-filled syringe
Friday, 16 Jun 2017 

June 15 (Reuters) - Adamis Pharmaceuticals Corp ::Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.Adamis pharmaceuticals receives FDA approval for its epinephrine pre-filled syringe.FDA has also approved PFS trade name of Symjepi.‍FDA approved Adamis' epinephrine injection, USP, 1:1000 for emergency treatment of allergic reactions including anaphylaxis​.Are preparing to submit second NDA for junior version of Symjepi to FDA.Expect to build inventory levels in preparation for anticipated launch in H2 of year for co's epinephrine pre-filled syringe.  Full Article

Swiss stocks - Factors to watch on Dec. 7

ZURICH/BERLIN, Dec 7 The Swiss blue-chip SMI was seen opening 1.2 percent higher at 8,765 points on Friday, according to premarket indications by bank Julius Baer .